Gabriel Étienne

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology · 2010 · 1.5K citations

Hematological Malignancy, Oncology, Chronic Myeloid Leukaemia +8

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 841 citations · Full text

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10